GSK - AbbVie GSK Teva cited as FTC tackles improper Orange Book patents
2023-11-07 12:53:17 ET
More on AbbVie, GSK, etc.
- Arexvy Puts GSK Back On The Growth Prescription (Rating Upgrade)
- GSK plc (GSK) Q3 2023 Earnings Call Transcript
- GSK plc 2023 Q3 - Results - Earnings Call Presentation
- J&J’s patent win against Viatris referred back to lower court
- Viatris Q3 2023 Earnings Preview
For further details see:
AbbVie, GSK, Teva cited as FTC tackles improper Orange Book patents